Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardiac Safety of Pegylated Liposomal Doxorubicin with Trastuzumab and Pertuzumab in Early HER2+ Breast Cancer
NCT05656079Unknown
- Sponsor
- Shanghai Pudong Hospital
- Start
- Jul 2021
- Primary completion
- Sep 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, open-label trial of pegylated liposomal doxorubicin in HER2-positive breast cancer (2 arms), sponsored by Shanghai Pudong Hospital. Primary endpoint: 1-year incidence of cardiotoxicity. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05656079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05656079.